Patent Law Weblog
recent posts
- Retired Judges File Amicus Brief in Support of Judge Newman
- Hikma v. Amarin at the Supreme Court: The Parties’ Opening Briefs
- Teva Pharmaceuticals International v. Eli Lilly & Co. (Fed. Cir. 2026)
- USPTO Extends Artificial Intelligence Search Automated Pilot Program (ASAP!)
- USPTO Announces That It Has Turned the Corner on Unexamined Application Backlog
about
Month: July 2007
-
By Donald Zuhn — On Monday, ARIAD Pharmaceuticals, Inc. announced that the U.S. District Court for the District of Massachusetts had ruled in its favor in a patent infringement suit ARIAD filed against Eli Lilly and Co. ARIAD and co-plaintiffs Massachusetts Institute of Technology, The Whitehead Institute for Biomedical Research, and The President…
-
By Kevin E. Noonan — More than 100 years ago, Mark Twain understood the corrosive power of numbers to sway a debate, particularly when those numbers are accepted unquestioningly and are based on faulty (but unspoken) assumptions. One example in patent law is the 85-97% patenting rate of patent applications set forth in…
-
By Donald Zuhn — As we reported two weeks ago, Roche commenced a cash tender offer on June 27, 2007 to acquire all outstanding shares of Ventana Medical Systems, Inc. common stock. In the past week, however, it appears that Roche’s acquisition of Ventana may have hit a snag – or two. Last…
-
By Sherri Oslick — About Court Report: Each week we will report briefly on recently filed biotech and pharma cases, and a few interesting cases will be selected for periodic monitoring. Codon Devices, Inc. v. febit Biotech GmbH et. al.1:07-cv-01177; filed June 29, 2007 in the District Court of the District of Columbia…
-
By Kevin E. Noonan — A measure of sanity returned last week, when the Brasilian Health Ministry and Abbott Laboratories announced an agreement on a pricing regime for Abbott’s anti-AIDS drug, Kaletra®. Under this agreement, Brasil will not "break" Abbott’s patent by permitting sale or importation of a generic version of the drug.…
-
By Christopher P. Singer — Alnylam Pharmaceuticals, Inc. and Roche announced on July 9, 2007 that they have entered into a non-exclusive license agreement in the area of RNA interference (RNAi) therapeutics. The agreement includes an upfront payment of $331 million from Roche to Alnylam, which includes cash payments, purchase of 1.975 million…
-
By Kevin E. Noonan — The course of litigation of Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co. (SMC) has been almost as lengthy as Jarndyce and Jarndyce, having been first filed in 1988. The case appeared again this week, when the Federal Circuit affirmed a District Court decision that prosecution history estoppel…
-
July 12-14, 2007 – Intellectual Property Law Summer Institute (Institute of Continuing Legal Education) – Mackinac Island, Michigan July 16-17, 2007 – Pharma and Biotech Collaborative Agreements Conference (American Conference Institute) – San Francisco, CA*** September 18-19, 2007 – Pharma/Biotech Patent Boot Camp (American Conference Institute) – San Francisco, IL*** September 26-27, 2007 – Advanced…
-
By Baltazar Gomez — On June 26, 2007, Denmark-based 7TM Pharma A/S announced the grant of United Kingdom patents covering the use of the Obinepitide and TM30339 for treating obesity. In 7TM Pharma’s statement, CEO Mette Kirstine Agger said the patents demonstrate the strength of 7TM Pharma’s patent position in the obesity area…
-
By Donald Zuhn — Applied Nanoscience Inc. announced today (July 6, 2007) that it has entered into a settlement agreement with NanoScale Coroporation. The agreement ends the lawsuit NanoScale filed against Applied Nanoscience, Emergency Filtration Products, Inc., Applied Nanoscience President Thomas K. Allen, and Emergency Filtration Products President and CEO Douglas K. Beplate,…
Patent Docs 